Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

AstraZeneca Expands Mississauga, Ontario, Canada, R&D Operations

01/27/2025
Global pharmaceutical company AstraZeneca plans to expand its R&D operations in Mississauga, Ontario, Canada. The $570 million project is expected to create 700 jobs.

The investment will include the relocation to a larger facility which will allow the company to enhance clinical trial design in oncology, immunology, and infectious diseases.

“AstraZeneca’s continued investment in Ontario is crucial to advancing innovative medicines that treat, prevent, and may one day cure complex diseases like prostate, lung, and breast cancer, as well as rare diseases. Canada, and specifically Ontario, offers a wealth of skilled talent and a robust network of world-class hospitals, universities, laboratories, and research centres. Collaborations like today’s with Invest Ontario reflect our shared commitment to strengthening the province’s life sciences strategy, driving economic growth, and fostering innovation that benefits patients in Canada and globally,” Gaby Bourbara, President of AstraZeneca Canada said.

Subject to reaching a definitive agreement, this project will be supported with a $16.1 million grant through the Invest Ontario Fund. In addition, Invest Ontario has provided the company with site selection services, market intelligence, and immigration support to streamline the investment process.

“AstraZeneca’s continued investment recognizes Ontario’s strength as a life sciences ecosystem and experienced talent needed for global innovative companies. We are proud to support AstraZeneca in harnessing AI and data to drive medical breakthroughs and improve healthcare outcomes for patients around the world,” Jennifer Block, Interim CEO of Invest Ontario noted.

Exclusive Research